Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
Colorcon
Johnson and Johnson
McKinsey
Medtronic

Last Updated: November 28, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,865,698


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,865,698 protect, and when does it expire?

Patent 8,865,698 protects VITRAKVI and is included in two NDAs.

This patent has one hundred patent family members in thirty-seven countries.

Summary for Patent: 8,865,698
Title:Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds
Abstract: Provided herein are methods for treating pain, cancer, inflammation, neurodegenerative disease or Typanosoma cruzi infection in a mammal, which comprises administering to said mammal in need thereof a therapeutically effective amount of a compound of Formula I: ##STR00001## in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, X, Y and n have the meanings given in the specification.
Inventor(s): Haas; Julia (Boulder, CO), Andrews; Steven W. (Boulder, CO), Jiang; Yutong (Boulder, CO), Zhang; Gan (Niwot, CO)
Assignee: Array BioPharma Inc. (Boulder, CO)
Application Number:13/943,590
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,865,698

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bayer Hlthcare VITRAKVI larotrectinib sulfate CAPSULE;ORAL 210861-001 Nov 26, 2018 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial METHOD OF TREATING CANCEROUS SOLID TUMORS ⤷  Free Forever Trial
Bayer Hlthcare VITRAKVI larotrectinib sulfate CAPSULE;ORAL 210861-002 Nov 26, 2018 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial METHOD OF TREATING CANCEROUS SOLID TUMORS ⤷  Free Forever Trial
Bayer Healthcare VITRAKVI larotrectinib sulfate SOLUTION;ORAL 211710-001 Nov 26, 2018 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial METHOD OF TREATING CANCEROUS SOLID TUMORS ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,865,698

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 074052 ⤷  Free Forever Trial
Argentina 112833 ⤷  Free Forever Trial
Australia 2009308465 ⤷  Free Forever Trial
Australia 2015200511 ⤷  Free Forever Trial
Australia 2017268517 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Mallinckrodt
Medtronic
Johnson and Johnson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.